Is invasive hydatidiform mole a malignant tumor?

Invasive mole is a malignant tumor. Invasive mole is a rare but highly aggressive gestational trophoblastic disease that originates from pregnancy-related tissue. Its malignant characteristics are mainly reflected in its ability to invade the myometrium of the uterus and may even spread to other parts of the body, such as the lungs and brain. This disease needs to be recognized and treated promptly to avoid further complications.

Symptoms of invasive mole usually include abnormal uterine bleeding, uterine enlargement, and a significant increase in hCG (human chorionic gonadotropin) levels that may not be consistent with the gestational period. Because these symptoms are not specific, it is difficult to diagnose them in the early stages in many cases. Early imaging examinations and histopathological analysis are crucial for diagnosis. Treatment is mainly based on combined chemotherapy, which has a good effect and allows most patients to achieve complete remission. Specific chemotherapy regimens often include methotrexate and actinomycin D. At the same time, surgical methods such as curettage can be used when necessary to remove residual diseased tissue in the uterus and ideally preserve the patient's fertility.

Symptoms of invasive mole usually include abnormal uterine bleeding, uterine enlargement, and a significant increase in hCG (human chorionic gonadotropin) levels that may not be consistent with the gestational period. Because these symptoms are not specific, it is difficult to diagnose them in the early stages in many cases. Early imaging examinations and histopathological analysis are crucial for diagnosis. Treatment is mainly based on combined chemotherapy, which has a good effect and allows most patients to achieve complete remission. Specific chemotherapy regimens often include methotrexate and actinomycin D. At the same time, surgical methods such as curettage can be used when necessary to remove residual diseased tissue in the uterus and ideally preserve the patient's fertility.

Early diagnosis and close follow-up are very important for the management and treatment of invasive hydatidiform mole. Regular monitoring of hCG levels can effectively evaluate the response to treatment and identify recurrence as early as possible. Patients should be careful to avoid getting pregnant again in the near future to reduce the risk of recurrence, and hCG monitoring should be performed after pregnancy to ensure that there are no signs of recurrence. Strictly following the doctor's advice during treatment and keeping abreast of the progress of the disease can help improve the cure rate and reduce the risk of complications.